Last week, as usual, wasn’t kind to biotech, and many of the stocks in our portfolio fell nearly 10% from their highs established just a week ago. Nonetheless, we continue to do press on with a clear vision of success.
Last week, as usual, wasn’t kind to biotech, and many of the stocks in our portfolio fell nearly 10% from their highs established just a week ago. Nonetheless, we continue to do press on with a clear vision of success.